RecoRNA (Hong Kong) Biotechnology Co., Ltd.
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Platform for Therapeutics
RecoRNA develops RNA‑targeted technologies to address diseases lacking effective treatments, with focus on genetic, neurologic, metabolic, and immuno‑oncology–addressable conditions. Our platform integrates a world‑leading RNA‑editing design engine built on the largest ADAR substrate library, an RNA fragment‑excision tool, and the AI‑driven ATOMIC screening system. These technologies enable the R&D of novel therapeutics that overcome limitations of traditional small‑molecule and biologic drugs while avoiding irreversible DNA‑editing risks. Our lead program is in an investigator‑initiated trial (IIT) for a genetic neurologic disorder, with additional early‑stage programs in metabolic and neuronal diseases. Xu Xin (Hong Kong) Biotech., our wholly owned subsidiary in the Hong Kong Science & Technology Park, has built an AI‑driven platform that accelerates drug discovery from target identification through hit‑molecule design, lead optimization, and candidate selection.
Company HQ City:
Guangzhou
Company HQ State:
Guangdong
Company HQ Country:
China
Year Founded:
2022
Lead Product in Development:
RC001
CEO
Rong Xin
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1 in investigator-initiated trial (IIT) stage, 3 in Discovery/Preclinical
When you expect your next catalyst update?
September-December 2026
What is your next catalyst (value inflection) update?
IIT data readout, IND submission, PCC (preclinical candidate) selection, next funding round
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}